Pliant Therapeutics (PLRX) Earnings Date & Reports

Key Takeaways

• Pliant Therapeutics (PLRX) is expected to report its third-quarter 2026 results around November 5, 2026, with Wall Street consensus pointing to a net loss of -$0.37 per share.
• The company is a clinical-stage biopharmaceutical developer, meaning revenue is minimal and the spotlight will fall squarely on operating expenses, cash burn, and clinical program updates.
• In the same period a year earlier, PLRX reported a loss of -$0.43 per share; last quarter (Q2 2026), it posted -$0.36, narrowly missing the -$0.34 consensus estimate.
• PLRX has beaten consensus EPS estimates in 5 of its last 8 quarters, but the stock has traded well below its 50-day and 200-day moving averages heading into this report.
• Investors will focus on the company's cash position, reported at roughly $158 million in the most recent quarter, and management's commentary on how far that capital will carry its pipeline.
• For more information on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, be sure to explore the dedicated pages for a fuller picture.
• You can also discover market opportunities using Trending AI Robots, which apply AI-driven signals to identify active trading ideas across the market.

Earnings Context and Why It Matters

Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapies, a field focused on proteins that regulate cell communication and tissue remodeling. With no meaningful product revenue, its quarterly earnings are less about top-line growth and more about disciplined spending, clinical progress, and the durability of its balance sheet. The stock has declined sharply over the past year, leaving a modest market capitalization and elevating the importance of every data point and management update. For investors, this report offers a checkpoint on whether the company's remaining cash can fund its most promising programs to their next milestones, and whether management's strategic pivot is resonating with the market.

Earnings Expectations

Analysts expect Pliant Therapeutics to report a net loss of approximately -$0.37 per share for the third quarter of 2026, compared with a loss of -$0.43 per share in the prior-year period. Revenue expectations are effectively negligible, reflecting the company's clinical-stage status. The most recent quarter provides a useful reference point: in Q2 2026, PLRX reported a loss of -$0.36 per share, missing the consensus estimate of -$0.34 by $0.02, while Q1 2026 delivered a -$0.32 result that beat the -$0.36 estimate. Historically, the stock has reacted to both the size of the loss and any pipeline commentary, with research-and-development spending trends and the pace of cash consumption among the most closely watched metrics this quarter.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. By automating what would otherwise be a manual, time-consuming process, the screener helps identify trade ideas, trending stocks, breakout candidates, and emerging market opportunities more efficiently. For investors tracking names like PLRX, it offers a streamlined way to surface comparable setups and monitor shifting market conditions.

Market Reaction and Investor Sentiment

Sentiment heading into this earnings event has been cautious. PLRX has been trading near its 52-week low and below both its 50-day and 200-day moving averages, signaling persistent selling pressure and limited bullish conviction. Analyst ratings remain mixed, with a consensus "Hold" designation and a wide range of price targets. The key risk factors investors are weighing include the rate of cash burn relative to the available runway, the timing and readout of clinical milestones, and the possibility of further financing or strategic actions. A result that shows tighter expense control or a clearer path to value-driving data could ease pressure, while any sign of accelerating costs or delayed catalysts may reinforce the stock's downward trend.

Forward Outlook and Key Factors to Monitor

Looking past this report, the central question for Pliant Therapeutics is capital adequacy. With roughly $158 million in cash on the most recent balance sheet and ongoing research-and-development spending, investors will watch for management's updated guidance on how many quarters of runway remain and whether additional financing may be needed.

Clinical execution is equally important. Progress updates, enrollment timelines, and data readout expectations across the company's pipeline programs will likely matter more to the long-term story than the size of any single quarterly loss. Any disclosure around strategic partnerships or restructuring could also shift the outlook.

Finally, cost discipline deserves close attention. Trends in research-and-development and general-and-administrative expenses will indicate whether the company is positioning itself to extend its runway and focus resources on its highest-priority assets. These factors, rather than revenue figures, will shape how investors interpret the results in the months ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations